Pfizer recall anti-smoking drug Chantix for high levels nitrosamine, which can increase cancer risk | Daily Mail Online

Date:

Pfizer has recalled its popular anti-smoking drug Chantix after it was found to contain high levels of cancer-causing agents called nitrosamines.

According to a notice posted on the Food and Drug Administration’s (FDA) website Thursday, the drug maker is ‘voluntarily recalling all lots of Chantix 0.5mg and 1mg tablets to the patient level due to the presence of a nitrosamine, N-nitroso-varenicline (NDMA), at or above the FDA interim acceptable intake limit’.

Then, in an update posted on Friday, the FDA advised ‘patients taking recalled varenicline to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different treatment’.

‘The health benefits of stopping smoking outweigh the cancer risk from the nitrosamine impurity in varenicline,’ it added.

Read full article here.

Shannon Thaler & Brian Stieglitz – Daily Mail – 2021-09-17.

Want More Investigative Content?

Curate RegWatch
Curate RegWatchhttps://regulatorwatch.com
In addition to our original coverage, RegWatch curates top stories on issues and impacts arising from the regulation of economic, social and environmental activity in Canada and the U.S.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

MORE VAPING

Industry Plot? | FDA Commissioner Denigrates Tobacco Harm Reduction | RegWatch

Does the regulator responsible for overseeing tobacco products in the U.S. believe in the practice of tobacco harm reduction? According to FDA Commissioner Robert...

Vaping Coverage Get it NOW!

Sign Up for Incisive Content!

RegWatch original video is designed to move opinion. Get our videos first and be the first to share.

Your Information will never be shared with any third party